| Literature DB >> 31660940 |
Clináscia Rodrigues Rocha Araújo1,2, Thiago de Melo Silva3, Michaelle Geralda Dos Santos4, Marcelo Henrique Fernandes Ottoni4, Elaine Maria de Souza Fagundes5, Humberto de Sousa Fontoura6, Gustavo Eustáquio Brito Alvim de Melo4, Antônio Flávio de Carvalho Alcântara3.
Abstract
BACKGROUND: Stem bark of Luehea ochrophylla (L. ochrophylla) is used by the traditional Brazilian medicine for treatment of rheumatic diseases and tumors. This study aimed to investigate inhibition of acute and chronic inflammations and cytotoxic activity of extracts, fractions, and isolated compounds from L. ochrophylla.Entities:
Keywords: Anti-inflammatory activity; Cytotoxic activity; Flavonoids; Luehea ochrophylla; Triterpenes
Year: 2019 PMID: 31660940 PMCID: PMC6819536 DOI: 10.1186/s12906-019-2701-7
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Chemical structure of the compounds isolated from stem bark of L. ochrophylla Mart: Friedelin (1), β-friedelinol (2), lupeol (3), pseudotaraxasterol (4), β-sitosterol (5), betulinic acid (6), taraxasterol (7), (−)-epicatechin (8), β-sitosterol-3-O-β-D-glucopyranoside (9), and (+)-epicatechin-(4β-8)-epicatechin (procyanidin B2) (10)
Fig. 2Histological aspect of the injured muscles of rat paws without treatment and treated for 24, 48, and 72 h with the application of gels with dexamethasone, hexane extract (HE), ethyl acetate fraction (AF), betulinic acid, β-sitosterol, β-sitosterol-3-O-β-D-glucopyranoside, and (−)-epicatechin. 10x magnification
Effect of EE extract and AF and EF fractions from stem bark of L. ochrophylla on cell viability after 24 h of culture
| Cell viability after 24 h | |||
|---|---|---|---|
| μg/mL | Mean | SD | |
| EE | 25.0 | 97.17a | 1.33 |
| EE | 50.0 | 89.17a | 6.59 |
| EE | 100.0 | 73.00b | 7.24 |
| AF | 50.0 | 96.33a | 1.63 |
| AF | 100.0 | 95.00a | 1.09 |
| AF | 200.0 | 77.83b | 7.55 |
| EF | 25.0 | 98.50a | 0.58 |
| EF | 50.0 | 93.33a | 3.14 |
| EF | 100.0 | 81.00b | 6.75 |
| CTRL | 98.00a | 1.09 | |
| DMSO | 97.67a | 0.82 | |
Values are expressed as mean ± standard deviation. Percentages of viable PBMC were assessed by using the trypan blue exclusion test (n = 8). Different letters in the same column indicate significant difference when (P < 0.05) after one-way ANOVA test with Tukey’s post hoc
Effect of EE extract and AF and EF fractions from stem bark of L. ochrophylla on cell viability after 5 days of culture
| Viability after 5 days | |||
|---|---|---|---|
| μg/mL | Mean | DP | |
| EE | 7.5 | 91.17a | 3.25 |
| EE | 15.0 | 92.67a | 2.58 |
| EE | 25.0 | 72.33b | 10.89 |
| AF | 25.0 | 87.17a | 5.27 |
| AF | 50.0 | 82.17a | 5.71 |
| AF | 100.0 | 54.17b | 13.89 |
| EF | 15.0 | 90.17a | 3.87 |
| EF | 25.0 | 81.33a | 12.53 |
| EF | 50.0 | 60.17b | 16.64 |
| CTRL | 92.17a | 3.19 | |
| DMSO | 92.67a | 2.58 | |
Values are expressed as mean ± standard deviation. Percentages of viable PBMC were assessed by using the trypan blue exclusion test (n = 8). Different letters in the same column indicate significant difference when (P < 0.05) after one-way ANOVA test with Tukey’s post hoc
Fig. 3Influence of EE extract and EF and AF fractions on the proliferation of activated lymphocytes. VPD 450-labeled human lymphocytes (5 × 105 cells) were cultured in the presence of medium, dexamethasone (DEXA, 8 μg/mL) or different concentrations of EE (7.5 and 15 μg/mL), EF (15.0 and 25 μg/mL), AF (25.0 and 50.0 μg/mL), and activated with PHA (5 μg/mL) for 5 days. The lymphocyte proliferation was analyzed using flow cytometry. The results are expressed as the mean ± SD of the proliferation index of human lymphocytes (n = 6). The ANOVA statistical method was used, followed by Tukey’s post hoc. * means significant difference (p < 0.05)
Effect of EE extract and AF and EF fractions from stem bark of L. ochrophylla on the proliferation of activated lymphocytes for 5 days
| Proliferation of lymphocytes index (PI) | |||
|---|---|---|---|
| μg/mL | Mean | DP | |
| EE | 7.5 | 0.85a | 0.12 |
| EE | 15.0 | 0.77a | 0.37 |
| AF | 25.0 | 0.70b | 0.20 |
| AF | 50.0 | 0.12b | 0.10 |
| EF | 15.0 | 1.10a | 0.45 |
| EF | 25.0 | 0.80a | 0.30 |
| Dexamethasone | 8.0 | 0.10b | 0.04 |
| PHA | 5.0 | 1.36a | 0.62 |
| Ctrl | 0.01b | 0.01 | |
| DMSO | 1.34a | 0.51 | |
Values are expressed as mean ± standard deviation. Different letters in the same column indicate significant difference when (P < 0.05) after one-way ANOVA test with Tukey’s post hoc
In vitro effect of lupeol and β-sitosterol-3-O-β-D-glucopyranoside on the proliferation of human cancer cell lines and non-tumorigenic cell line (Vero cells)
| Compounds | MDA-MB-231 | MCF-7 | HCT-116 | Vero | |||
|---|---|---|---|---|---|---|---|
| IC50 ± SD | SI | IC50 ± SD | SI | IC50 ± SD | SI | IC50 ± SD | |
| Lupeol | 60 ± 17.2 | 0.8 | 67 ± 22.4 | 0.8 | 35.2 ± 13.2 | 1.5 | 51 ± 18.2 |
| 33 ± 10.1 | 0.6 | 11 ± 5.2 | 1.9 | 1.279 ± 0.7 | 16.4 | 21 ± 9.9 | |
| Cisplatin | > 100 | > 100 | > 100 | 13.05 ± 0.6 | |||
Data are presented as mean ± SD. IC50 50% inhibition of cell growth. SI Selectivity index calculated as follows IC50 (μg/mL) for Vero / IC50 (μg/mL) for tumor cells